Abstract:Introduction Gastric cancer (GC) is the fourth most common cancer and the third-leading cause of cancer-related deaths worldwide. Despite certain advances in chemotherapy regimens and targeted therapies, the 5 year survival of patients with advanced GC is disappointing. The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC) refractory to two or more lines of prior systemic chemotherapies. However, a dose reduction or treatment interruption is required to prevent apatinib toxicity such as hand-foot skin reaction (HFSR), proteinuria, and hypertension. In addition, suitable biomarkers are not accessible for identifying the patients who are most likely to benefit from apatinib. Therefore, predictive biomarkers are urgently needed to reduce toxicity and identify patients that will benefit from apatinib treatment. Material and methods Clonogenic assay, cytotoxicity assay, apoptosis assay, qRT-PCR, western blot were conducted in GC cells to evaluate the effectiveness of apatinib in vitro. Confocal microscopy assay was peformed to examine apatinib-induced autophagic flux in GC cells. Transmission electron microscopy assay was conducted to show the formation of autophagic vesicles. Xenograft models in mice were conducted and six tumour tissues were sent for miRNA-seq and circRNA-seq. Sanger sequencing was applied to determine the full length of the amplification products. Results and discussions In this study, we found that apatinib inhibited the growth of GC cells and xenograft tumours. Apatinib promoted autophagy activation via upregulation of ATG7 expression, and autophagy inhibition enhanced apatinib-induced apoptosis. With miRNA-seq and circRNA-seq analyses of GC xenograft models, we demonstrated that circRNA004582 functioned as an endogenous sponge for miR-3657 to inhibit its activity and further upregulate ATG7 expression. Silencing of circRNA004582 inhibited apatinib-induced autophagy, which was rescued by miR-3657. Moreover, knockdown of circRNA004582 promoted apatinib-induced apoptosis in GC cells. These findings provided the first evidence that the circRNA004582-miR-3657-ATG7 axis mediates a regulatory pathway critical for the regulation of autophagy and apatinib sensitivity in GC cells and xenografts. Conclusion In conclusion, specific blockage of circRNA004582 may be a potential therapeutic target for autophagy inhibition in the context of apatinib treatment in human GC. Prospective clinical studies are warranted to examine these biomarkers.

All-trans retinoic acid-mediated miR-30a up-regulation suppresses autophagy and sensitizes gastric cancer cells to cisplatin

Autophagy Inhibition and Sensitization to Cisplatin in Esophageal Cancer Stem-Like Cells via All-trans Retinoic Acid-induced miR-30a

Propofol Facilitates Cisplatin Sensitivity Via Lncrna MALAT1/miR-30e/ATG5 Axis Through Suppressing Autophagy in Gastric Cancer.

Downregulation of Microrna-17-5p Inhibits Drug Resistance of Gastric Cancer Cells Partially Through Targeting P21.

Resveratrol Synergizes with Cisplatin in Antineoplastic Effects Against AGS Gastric Cancer Cells by Inducing Endoplasmic Reticulum Stress‑mediated Apoptosis and G2/M Phase Arrest.

Microrna-30a Sensitizes Tumor Cells to Cis-Platinum Via Suppressing Beclin 1-Mediated Autophagy

Regulation of Autophagy by Mir-30D Impacts Sensitivity of Anaplastic Thyroid Carcinoma to Cisplatin.

miR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin.

MicroRNA-148a-3p Enhances Cisplatin Cytotoxicity in Gastric Cancer Through Mitochondrial Fission Induction and Cyto-Protective Autophagy Suppression.

Mir-21 Modulates Cisplatin Resistance of Gastric Cancer Cells by Inhibiting Autophagy Via the PI3K/Akt/mTOR Pathway

Targeted Inhibition of CCL22 by miR-130a-5p Can Enhance the Sensitivity of Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy

miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2

ATRA promotes PD-L1 expression to control gastric cancer immune surveillance

Targeting Oncogenic Mir-181A-2-3p Inhibits Growth and Suppresses Cisplatin Resistance of Gastric Cancer.

Inhibition of Autophagy Improves Resistance and Enhances Sensitivity of Gastric Cancer Cells to Cisplatin.

miR-107 reverses the multidrug resistance of gastric cancer by targeting the CGA/EGFR/GATA2 positive feedback circuit

PO-071 Silencing of Circrna004582 Sensitises Gastric Cancer Cells to APATINIB Via Modulating Autophagy by Targeting Mir-3657 and ATG7

Mechanism of cisplatin resistance in gastric cancer and associated microRNAs

MiR-32 induces radio-resistance by targeting DOC-2 / DAB 2 interactive protein and regulating autophagy in gastric carcinoma

The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin

MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer